Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Was hoping for at least $1.74 Ten min. to go!
I need to leave the room for a few minutes - I wonder what I'll return to!?!?!?!
It sure wants to! WEEeeeee!
We may close HIGHER than $1.75....It wants to FLY!
Good job! Just be careful....
Clotamin? Hell we need PeptoBismol here! That was a dizzy rollacoaster ride - and QUICK!
MAX is SQUEALING for JOY!! WEEEEEEEEEEEeeeeeeee
SNPK = TOWER of POWER!! Every hour!
New HOD soon??
Pretty WILD Power Hour!
JD Love didn't lose. He made $1.00 share PROFIT!! That's GREAT and doesn't happen often here in stinky pinky land..... Although LOVE the smell of SNPK!
Yes, but not enough to buy more...but I'm not complaining... By the way, I DID get a PM from the person we talked about with the same answer you gave me! He just must be busy. I had asked him a while back too!
Best of luck to you and ALL of us!
Hope the dip catapults us to the NEXT level!
Article is from Seeking Alpha.
SNPK being compared to Facebook/Instagram deal:
Facebook's Instagram Acquisition Highlights Why Sunpeaks Is Attractive
April 12, 2012 | 4 comments | about: SNPK.OB, includes: FB, WAG, WINN
Takeover talk generates a lot of buzz in the market as investment bankers and investors get excited for fast money. Why investors and investment bankers? Well, investors get an immediate return on their investment and investment bankers get large transaction fees. The M&A market has seen an increase in interest this week after Facebook's (FB) $1 billion acquisition of Instagram, a fun, popular photo-sharing app for mobile devices. If that wasn't enough, Facebook's initial public offering is expected to take place next month so it's a hot time, to say the least, in the M&A markets.
Digging deeper into the press release, Mark Zuckerberg said that Facebook and Instagram "complement each other" and that is one reason why acquisitions are done. That same reason is why Sunpeaks Ventures (SNPK.OB) could be attractive for potential acquirers. For some background, Sunpeaks Ventures and its wholly owned subsidiary Healthcare Distribution Specialists ("HDS") is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin.
Although relatively new to the market, the stock is generating a lot of excitement and interest, more than doubling over the past few weeks. Investors seem to be attracted to the company's growth strategy and the speed with which it has established new distribution partnerships for its top product, Clotamin. Some of its new partners include Walgreens (WAG) and Winn-Dixie (WINN). Clotamin is obviously getting recognition by some of the largest retailers in the U.S., and with that, comes interest from larger players looking to bolt on acquisitions to expand their product line and those looking for growth.
Sunpeaks' potential acquirers are not just getting domestic distribution partnerships. This week the company announced two international expansions. On Monday, the company said that it signed a Letter of Intent with PharmaLife for placement of Clotamin with leading pharmacies in the Russian Federation.
The Letter of Intent outlines the terms and conditions of a proposed transaction that could see Clotamin distributed by several pharmacy and retail chains in the Russian Federation, including product placement with leading wholesalers Imperia-Pharma, the Dr. Stoletov pharmacy chain (414 locations), and other small retail pharmacies associated with Imperia-Pharma. PharmaLife is also expected to secure timely product registration within the Russian Federation for Clotamin distribution and conduct local market research to support a successful product launch.
This expansion may set the table for the company expanding into other international markets. Mackie A Barch, CEO of SNPK, said that "we look forward to working closely with PharmaLife and our new possible distributors to build market awareness and sales of Clotamin across Russia. If successful, the company intends to utilize this expansion strategy to penetrate other international markets that share similar potential."
On Wednesday, Sunpeaks announced that it entered into an agreement with DS Healthcare Limited to assist in introducing Clotamin to the UK/EU market. Under terms of the agreement, DS Healthcare will evaluate the Clotamin formulation and claims against the European Union Food Supplement Directive, the Nutritional Health Claims Directive, and Food Labeling Regulations to determine any specific actions and timeline required to introduce Clotamin to the U.K./EU market.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
This article was sent to 150 people who get email alerts on SNPK.OB.
Get email alerts on SNPK.OB »
This article is tagged with: Long & Short Ideas, Long Ideas, Basic Materials
SNPK being compared to Facebook/Instagram deal:
Facebook's Instagram Acquisition Highlights Why Sunpeaks Is Attractive
April 12, 2012 | 4 comments | about: SNPK.OB, includes: FB, WAG, WINN
Takeover talk generates a lot of buzz in the market as investment bankers and investors get excited for fast money. Why investors and investment bankers? Well, investors get an immediate return on their investment and investment bankers get large transaction fees. The M&A market has seen an increase in interest this week after Facebook's (FB) $1 billion acquisition of Instagram, a fun, popular photo-sharing app for mobile devices. If that wasn't enough, Facebook's initial public offering is expected to take place next month so it's a hot time, to say the least, in the M&A markets.
Digging deeper into the press release, Mark Zuckerberg said that Facebook and Instagram "complement each other" and that is one reason why acquisitions are done. That same reason is why Sunpeaks Ventures (SNPK.OB) could be attractive for potential acquirers. For some background, Sunpeaks Ventures and its wholly owned subsidiary Healthcare Distribution Specialists ("HDS") is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin.
Although relatively new to the market, the stock is generating a lot of excitement and interest, more than doubling over the past few weeks. Investors seem to be attracted to the company's growth strategy and the speed with which it has established new distribution partnerships for its top product, Clotamin. Some of its new partners include Walgreens (WAG) and Winn-Dixie (WINN). Clotamin is obviously getting recognition by some of the largest retailers in the U.S., and with that, comes interest from larger players looking to bolt on acquisitions to expand their product line and those looking for growth.
Sunpeaks' potential acquirers are not just getting domestic distribution partnerships. This week the company announced two international expansions. On Monday, the company said that it signed a Letter of Intent with PharmaLife for placement of Clotamin with leading pharmacies in the Russian Federation.
The Letter of Intent outlines the terms and conditions of a proposed transaction that could see Clotamin distributed by several pharmacy and retail chains in the Russian Federation, including product placement with leading wholesalers Imperia-Pharma, the Dr. Stoletov pharmacy chain (414 locations), and other small retail pharmacies associated with Imperia-Pharma. PharmaLife is also expected to secure timely product registration within the Russian Federation for Clotamin distribution and conduct local market research to support a successful product launch.
This expansion may set the table for the company expanding into other international markets. Mackie A Barch, CEO of SNPK, said that "we look forward to working closely with PharmaLife and our new possible distributors to build market awareness and sales of Clotamin across Russia. If successful, the company intends to utilize this expansion strategy to penetrate other international markets that share similar potential."
On Wednesday, Sunpeaks announced that it entered into an agreement with DS Healthcare Limited to assist in introducing Clotamin to the UK/EU market. Under terms of the agreement, DS Healthcare will evaluate the Clotamin formulation and claims against the European Union Food Supplement Directive, the Nutritional Health Claims Directive, and Food Labeling Regulations to determine any specific actions and timeline required to introduce Clotamin to the U.K./EU market.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
This article was sent to 150 people who get email alerts on SNPK.OB.
Get email alerts on SNPK.OB »
This article is tagged with: Long & Short Ideas, Long Ideas, Basic Materials
He sends out emails like APS and the others. His site is:www.pickpennystocks.net
Most of his picks have been dogs for me...bu looks like he did good on this one!
I didn't say 'daytrade' it...I've been in this one since the first Friday freefall. Got filled at .41 even though my limit oder was set at .4399! Then got some more at .60 during the 2nd freefall 2 Friday's ago I believe it was. My avg. is .4219 and I'm still all in too. I have my sells set in increments....
Good Luck to us ALL!
FLY SNPK. FLY like MAX!!!!!!!!!!!!!!!
Thanks ilenes - that helped a lot.
I don't know. Maybe someone else here can answer that one. I'm going to call ETrade today and ask...
I would sell enough to get your origingal money out and take a profit that makes you very happy. If you want to keep FREE shares after that - it's your life/money, but 99.999% of EVERYONE here believe this is nothing more than a short term play - no further than maybe a few more weeks from now AT BEST. Good Luck. I used to "believe" in penny companies with a great story too - until they ALL kept taking my money via end-of-promo (pump) quick crashes) and reverse splits. You want to 'date; these suckers, NOT 'marry' them.
I'm guessing Stop Losses don't work during a crash because the share price is dropping faster than they can fill orders..... I guess they're only good on stable stocks - big boards, etc, but I know NOTHING of the details.
I have been told not to use them or the MMs will "stop you out" - grab your shares at your low price, and then let the price rise again....
Anyone using Stop Losses? They don't always work though right? If a stock drops like 2 Friday's ago?
Only alternative to sit here? Don't get me wrong - TODAY it's FUN!!
WEEEEEEEEEEEEEEEEEEEEEeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee !!!
Sure doesn't look like any pullback is in site today! Maybe $2's for LUNCH!
We We WEEEEEeeeeeeeee!!!!!
It's like watching PacMan gobbling up those shares!
I think da BIG RUN has BEGUN!
Anyone using stop losses? Should we, rather than have to sit here all day until how many days from now?
Mornin' Kenswift. 'Nother new HIGH $1.65
WE WE WEEEEEEEEEEEEEEEEeeeeeeeeeeeeeeeeeeeee!!!!!!!!!
Pigs CAN FLY!! Just watch MAX on the ZipLine! WEEEEEeeeee
GO MAX GO!
GO SNPK GO GO GO GO GO GO where no APS stock has ever gone before!!!!!!!!!!!!!!!
Can you say WEEEEEEEeeeeeee!!!!
GO SNPK GO GO GO GO GO to &9.00 LOL
Here's the $9.00 Target for SNPK Report:
Sunpeaks Ventures, Inc. (OTCBB: SNPK) Featured By Small Cap Investment Research
Small Cap Investment Research (SmallCapInvestmentResearch.com), a developer, publisher and marketer of independent research products, announced today the release of an updated research report on Sunpeaks Ventures, Inc.
(EMAILWIRE.COM, April 11, 2012 ) Los Angeles, CA -- Small Cap Investment Research (SmallCapInvestmentResearch.com), a developer, publisher and marketer of independent research products, announced today the release of an updated research report on Sunpeaks Ventures, Inc (OTCBB: SNPK) (“the Company”). Small Cap Investment Research has issued a “STRONG BUY” and a target price of $9.00 on shares of this company.
The report examines the potential continued growth of the Company as it continues to gain market share, and examines the outlook for short and long-term investors. “We were pleased to have the opportunity to report on this company and the industry factors that affect it. The report presents a great overview of the Company and its potential for the long-term with a constantly improving industry dynamic.” – Small Cap Investment Research.
Recently, Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") announced that HDS has signed a Letter of Intent with PharmaLife® for placement of Clotamin® with leading pharmacies in the Russian Federation.
The Letter of Intent outlines the terms and conditions of a proposed transaction that could see Clotamin distributed by several pharmacy and retail chains in the Russian Federation, including product placement with leading wholesalers Imperia-Pharma, the Dr. Stoletov pharmacy chain (414 locations), and other small retail pharmacies associated with Imperia-Pharma. PharmaLife is also expected to secure timely product registration within the Russian Federation for Clotamin distribution and conduct local market research to support a successful product launch.
The entire report can be found on http://www.smallcapinvestmentresearch.com/featured-companies/ .
About Small Cap Investment Research:
Small Cap Investment Research specializes in providing readers with an in-depth analysis of undervalued companies. The company’s role as an independent research analyst firm is to “separate the wheat from the chaff” and help investors receive unbiased, thought-provoking, and quality investment research. SCIR’s philosophy in research is to encapsulate realistic investment ratings, target prices, and forward-looking financial models. The reports contain hard-hitting, meticulously researched facts on companies, their fundamentals, and their industries, validating a company’s prospects and enabling the reader to objectively evaluate the company’s value. The media and savvy investors alike view this model as how investment research needs to be performed devoid of any partiality.
About Sunpeaks Ventures, Inc.:
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.
Forward-Looking Statements
Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of Sunpeaks Ventures, Inc. (OTCBB: SNPK) can be found in the filings of Sunpeaks Ventures, Inc. with the U.S. Securities and Exchange Commission.
Release of Liability: Through use of this website viewing or using you agree to hold SCIR, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. We have been compensated six thousand dollars for this SNPK report. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCIR encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCIR makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies.
Contact Information:
Indepedent Research Investment
Derrick Brazinski
Tel: 3104567798
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php
"May be your last chance to buy under $2"! From tonight's APS and their other assoc. emails!!!! LOL
Boy - those are FIGHTIN' WORDS!!! LOL
Guess we may have 14 more days +/-
I thought today was a disaster here after the promising action yesterday - up until just before and into the close.....
The hopeful part of this is - IF news is REALLY coming this week - it should be tomorrow as companies rarely release news on Fridays!!!
Good Luck to us ALL!
FLY Limos FLY!!!!!!!
To all still holding: How are you splitting up your sell orders? Just curious...
I have 3840 at a .4219 average. (Got 3600 at .41 on the first big drop and 240 @ .60 on the last one). I was going to hold all of it until $2.20, and then sell 1440 @ $2.20 for a double AND have 2400 FREE shares. Then sell 1000 @ $3, 1000 @ $4 and watch what happened to the other 400!?!?! Whether the last 400 go to $8, $10, $12 or BUST - they were FREE and I already banked $ 8,500 pig (as in MAX) money!!! WEEEEeeeee TIA
Good Luck to us ALL!
GO SNPK GO GO GO GO GO GO GO all the way to London, Rome, St. Petersburg (RUSSIA - not Florida - LOL), Madrid, Frankfurt, Holland, Japan, the MOON, the Stratosphere and ALL our BANK ACCOUNTS !!!!!!!!!!!!!!
Did you hear THAT!?!?!?! The POPE is taking Clotamin!!! LOL
Now we're going to EUROPE!! NEWS!!:
Sunpeaks Ventures Enters Agreement with UK Based Healthcare Firm to Introduce Clotamin to UK and European Union Countries
SILVER SPRING, Md., April 11, 2012 /PRNewswire/ --Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that HDS has entered into an agreement with DS Healthcare Limited to assist in introducing Clotamin to the UK/EU market.
Under terms of the agreement, DS Healthcare will evaluate the Clotamin formulation and claims against the European Union Food Supplement Directive, the Nutritional Health Claims Directive, and Food Labeling Regulations to determine any specific actions and timeline required to introduce Clotamin to the UK/EU market.
"The UK and European Union market represent an enormous opportunity to expand Clotamin distribution into new territories and reach millions of new potential Clotamin users. The agreement with DS Healthcare is the first step towards achieving that goal," stated Mackie A. Barch, CEO of Sunpeaks Ventures. "We intend to fully utilize their extensive technical, commercial, and regulatory expertise to build and launch the Clotamin brand across Europe."
DS Healthcare Limited are experts in the UK/EU natural healthcare sector and currently distribute numerous products to the market. The company also provides consultancy services to select healthcare businesses, including pet and equine, right across the entire supply chain from new product development to marketing.
About Sunpeaks Ventures, Inc.
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.
For additional information, please visit www.sunpeaksventures.com.
Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Sunpeaks Ventures, Inc.
Source: PR Newswire (April 11, 2012 - 5:28 PM EDT)
Kenswift, what do you consider a healthy dip? TIA. I respect your opinions and LOVE what you've done to MAX!
Who SAYS "You can put lipstick on a pig but it's still a pig? Our pig sings WEEEEEEEEeeeee ALL the WAY to the SNPK BANK!!
LOL - Oh yeah - it was a pitbull!!!!
Kenswift: This just happened: I went to the store after closing bell, and when I came out and was in the parking lot, I heard a young child crying or screaming - BUT - you ready??? It came out sounding JUST LIKE MAX says: WEEEEeeeeeeeeeeeeeeeeeeeee!!!! LOL
QUESTION: Why did so many people here go from "This is going to $2, $3 and MORE only YESTERDAY - to "SELL SELL SELL it's going to CRASH today?
All opinions and thoughts invited! Thanks.
GO SNPK GO GO GO GO So Super MAX can keep going WEEEeeeeeeeeee!!!!!!!!!!!!!
Good one! Since you just got in today at 1.55 and 1.56, How high do you think it will really go? Or at least, what is your target to sell? TIA